Risk factors

Grove faces significant risks related to consumer discretionary spending, advertising and marketing claims, and net losses totaling $648.5 million.

This is Immunome's initial risk disclosure as a public company, reflecting a clinical-stage biotechnology business. Major risks center on clinical trial execution, heavy capital requirements, and heavy reliance on third-party manufacturers. The pipeline features key candidates including varegacestat, IM-1021, and IM-3050.

Century Therapeutics faces significant recurring losses and is dependent on advancing its lead allogeneic cell therapy candidate, CNTY-101. The company relies heavily on specialized manufacturing platforms and strategic partnerships like Bayer and FCDI. Nasdaq listing compliance regarding minimum bid price is an immediate operational concern.

LENZ Therapeutics relies entirely on the success of LNZ100 for presbyopia, pending FDA review of its NDA submitted in August 2024. The company depends on third-party manufacturers, international partners like CORXEL in Greater China, and robust intellectual property protection for aceclidine.

Company relies heavily on external management and 30-day term SOFR indexing for floating-rate commercial mortgage loans. Portfolio is focused on transitional multifamily and commercial real estate loans subject to credit and market risks. Valuation of assets, credit loss provisions, and interest rate fluctuations heavily impact financial results.

Navitas relies heavily on long semiconductor sales cycles and design wins in mobile, solar, EV, and industrial markets. Single-source foundries fabricate its gallium nitride and silicon carbide power chips, exposing operations to supply constraints. Substantial revenue comes from China, exposing the company to geopolitical trade restrictions and the U.S. Outbound Investment Security Program.

Company is heavily concentrated in New York City real estate, faces active covenant breaches on major mortgages, and is expanding into non-REIT assets.

Substantial doubt about going concern given $2.1B accumulated deficit and reliance on PRGN-2012 for RRP.

Plumas Bancorp faces high geographic concentration in Northern California and Northern Nevada. Real estate loans represent approximately 77% of its total portfolio. Growth is heavily focused on the pending merger with Cornerstone Community Bancorp.

Perpetua Resources faces going concern risks with cash reserves exhausting by the third quarter of 2025.

Oil and gas price volatility and OPEC policies drive distributions.

Signet's risks are dominated by supply chain and commodity price volatility for diamonds and gold, consumer financing dependencies, and activist shareholder pressure.